IP Library Granted Patent US 8,344,742
Granted Patent B2
US 8,344,742 · App. 13/011,725 · Granted Jan 1, 2013

Real time electronic cell sensing system and applications for cytotoxicity profiling and compound assays

Assignee: ACEA Biosciences, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,344,742
App. No.
13/011,725
Granted
Jan 1, 2013
Kind
B2
Abstract

The invention provides methods of investigating a mechanism of action of a compound, which includes providing a device for monitoring cell-substrate impedance; attaching the device to an impedance analyzer; adding cells to two or more wells; adding a test compound to at least one of the wells and providing at least one control well; monitoring impedance of the wells to obtain a series of impedance measurements; plotting impedance measurements to obtain impedance curves and comparing the impedance curves to determine a time frame at which the test compound has a significant effect on cell growth or behavior. Determining the time frame provides information on changes in cell status in response to the test compound, including cell attachment or adhesion status, cell growth or proliferation status, the number of viable or dead cells, cytoskeletal organization or structure, and the number of cells going through apoptosis or necrosis.

Claims (37)

1. A method of investigating a mechanism of action of a compound, comprising:

providing a device for monitoring cell-substrate impedance, wherein the device comprises two or more wells, each comprising an individually addressable electrode array, further wherein each electrode array comprises two electrode structures, each of which comprises multiple electrode elements, further wherein the electrode structures of each electrode array have substantially the same surface area;

attaching the device to an impedance analyzer;

adding cells to two or more wells;

adding a test compound to at least one of the wells comprising cells to form at least one test compound well;

providing at least one control well comprising cells that does not receive test compound;

monitoring impedance of the at least one test compound well and the at least one control well to obtain a series of impedance measurements including before adding the test compound and three or more time points after adding the test compound;

plotting impedance measurements from the at least three time points versus time to obtain at least one test compound impedance curve and at least one control impedance curve; and

comparing the impedance curves from the at least one test compound well and the at least one control well to determine a time frame at which the test compound has a significant effect on cell growth or behavior, wherein determining the time frame provides information on changes in cell status in response to the test compound, wherein the cell status is selected from the group consisting of cell attachment or adhesion status, cell growth or proliferation status, the number of viable or dead cells, cytoskeletal organization or structure, and the number of cells going through apoptosis or necrosis.

2. The method according to claim 1 , wherein monitoring impedance comprises monitoring impedance at regular or irregular time intervals.

3. The method according to claim 1 , wherein the cells are selected from the group consisting of mammalian cells, human cells, cancer cells, genetically modified cells and cells infected with virus.

4. The method according to claim 1 , wherein the test compound is selected from the group consisting of a small molecule, an organic molecule, a steroid, a peptide and a nucleic acid.

5. The method according to claim 1 , further comprising deriving a cell index, a normalized cell index, or a delta cell index from impedance measurements from the at least one test compound well and the at least one control well.

6. The method according to claim 5 , further comprising plotting the cell indices, the normalized cell indices, or the delta cell indices versus time to provide at least one test compound CI curve and at least one control CI curve,

7. The method according to claim 5 , further comprising deriving a cell change index (CCI) from the impedance measurements from the at least one test compound well and from the at least one control well.

8. The method according to claim 7 , further comprising determining the CCI at a given time point for the at least one test compound well and the at least one control well as being either: approximately equal to 0.7, much greater than 0.7, greater than zero and less than 0.7, approximately equal to zero, less than zero, or much less than zero;

wherein a CCI approximately equal to 0.7 indicates log rate growth, a CCI much greater than 0.7 indicates faster than log rate growth, a CCI greater than zero and less than 0.7 indicates slower than log rate growth, a CCI approximately equal to zero indicates no growth, a CCI less than zero indicates cells are detaching from the substrate, and a CCI much less than zero indicates cell are detaching rapidly from the substrate.

9. The method according to claim 1 , wherein the one or more test compound wells comprise two or more test compound wells and the method further comprises plotting cell index, normalized cell index, or delta change index versus concentration for at least one time point to generate one or more dose response curves for one or more time points at which impedance is measured.

10. The method according to claim 9 , wherein the one or more dose-response curves are used to calculate a time-dependent IC value selected from the group consisting of IC5, IC10, IC20, IC30, IC40, IC50, IC60, IC70, IC80, IC90, and IC95 at one or more time points for the test compound.

11. The method according to claim 10 , further comprising using the one or more dose-response curves to calculate one or more time-dependent IC50 values for the test compound for one or more time points.

12. The method according to claim 1 , wherein the test compound is selected from the group consisting of a small molecule, an organic molecule, a steroid, a peptide and a nucleic acid.cancer cells, genetically modified cells and cells infected with virus.

13. A method of investigating a mechanism of action of a compound, comprising:

providing a device for monitoring cell-substrate impedance, wherein the device comprises two or more wells, each comprising an individually addressable electrode array, further wherein each electrode array comprises two electrode structures, each of which comprises multiple electrode elements, further wherein the electrode structures of each electrode array have substantially the same surface area;

attaching the device to an impedance analyzer;

adding cells to two or more wells;

adding a test compound to at least one of the wells comprising cells to form at least one test compound well;

providing at least one control well comprising cells that does not receive test compound;

monitoring impedance of the at least one test compound well and the at least one control well to obtain a series of impedance measurements including before adding the test compound and three or more time points after adding the test compound;

deriving a cell index, a normalized cell index, or a delta cell index from the impedance measurements from the at least one test compound well and the at least one control well;

plotting the cell indices, the normalized cell indices, or the delta cell indices to provide at least one test compound concentration CI curve and at least one control CI curve; and

comparing the CI curves from the at least one test compound well and the at least one control well to determine a time frame at which the test compound has a significant effect on cell growth or behavior, wherein determining the time frame provides information on changes in cell status in response to the test compound, wherein the cell status is selected from the group consisting of cell attachment or adhesion status, cell growth or proliferation status, the number of viable or dead cells, cytoskeletal organization or structure, and the number of cells going through apoptosis or necrosis.

14. The method according to claim 13 , wherein monitoring impedance comprises monitoring impedance at regular or irregular time intervals.

15. The method according to claim 13 , wherein the cells are selected from the group consisting of mammalian cells, human cells, cancer cells, genetically modified cells and cells infected with virus.

16. The method according to claim 13 , wherein the one or more test compound wells comprise two or more test compound wells and the method further comprises plotting cell index, normalized cell index, or delta change index versus concentration for at least one time point to generate one or more dose response curves for one or more time points at which impedance is measured.

17. The method according to claim 16 , wherein the one or more dose-response curves are used to calculate a time-dependent IC value selected from the group consisting of IC5, IC10, IC20, IC30, IC40, IC50, IC60, IC70, IC80, IC90, and IC95 at one or more time points for the test compound.

18. The method according to claim 17 , further comprising using the one or more dose-response curves to calculate one or more time-dependent IC50 values for the test compound for one or more time points.

19. The method according to claim 16 , further comprising deriving a cell change index (CCI) from the impedance measurements from the one or more test compound wells and from the at least one control well.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 25, 2021
From: ACEA BIOSCIENCES, INC.
To: AGILENT TECHNOLOGIES, INC.
Reel/Frame 055409/0874 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 26, 2011
From: XU, XIAO; ABASSI, YAMA; WANG, XIAOBO
To: ACEA BIOSCIENCES, INC
Reel/Frame 025703/0732 →
Continuity (12)
Continuation 12480592 · Jun 8, 2009
Division 11055639 · Feb 9, 2005
Continuation In Part 10987732 · Nov 12, 2004
Continuation In Part 10705447 · Nov 10, 2003
Continuation In Part 10705615 · Nov 10, 2003
Provisional Application 60519567 · Nov 12, 2003
Provisional Application 60435400 · Dec 20, 2002
Provisional Application 60469572 · May 9, 2003
Provisional Application 60542927 · Feb 9, 2004
Provisional Application 60548713 · Feb 27, 2004
Provisional Application 60614601 · Sep 29, 2004
Related Publication 20110117542A1 · May 19, 2011